Anti-inflammatory effect of ketamine versus dexmedetomidine in laparoscopic hysterectomy
Phase 3
Recruiting
- Conditions
- Urological and Genital DiseasesAnaesthesia
- Registration Number
- PACTR201910617459894
- Lead Sponsor
- amees Mohamed Dawood
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 75
Inclusion Criteria
seventy five female patients,
aged 30-60,
ASA physical status I –II,
scheduled for elective laparoscopic hysterectomy
Exclusion Criteria
patient refusal,
severe respiratory or cardiac disorders,
hepatic or renal insufficiency,
allergy to any of the study drugs,
severe obesity (body mass index >35 kg m-2),
uncontrolled diabetes,
use of any drug that might affect the immunity as chemotherapy or hormonal treatment.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie ketamine's anti-inflammatory effects in laparoscopic hysterectomy?
How does ketamine compare to dexmedetomidine in modulating cytokine release during laparoscopic surgery?
Are there specific biomarkers that predict differential response to ketamine or dexmedetomidine in gynecological anesthesia?
What are the potential adverse events associated with intraoperative ketamine use in gynecological procedures?
How do NMDA receptor antagonism and alpha-2 agonism influence postoperative inflammation in laparoscopic hysterectomy?